200 related articles for article (PubMed ID: 19720291)
1. Bifunctional phage-based pretargeted imaging of human prostate carcinoma.
Newton-Northup JR; Figueroa SD; Quinn TP; Deutscher SL
Nucl Med Biol; 2009 Oct; 36(7):789-800. PubMed ID: 19720291
[TBL] [Abstract][Full Text] [Related]
2. Melanoma imaging with pretargeted bivalent bacteriophage.
Newton JR; Miao Y; Deutscher SL; Quinn TP
J Nucl Med; 2007 Mar; 48(3):429-36. PubMed ID: 17332621
[TBL] [Abstract][Full Text] [Related]
3. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.
Patil V; Gada K; Panwar R; Varvarigou A; Majewski S; Weisenberger A; Ferris C; Tekabe Y; Khaw BA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):824-39. PubMed ID: 22302089
[TBL] [Abstract][Full Text] [Related]
4. Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.
Newton-Northup JR; Figueroa SD; Deutscher SL
Comb Chem High Throughput Screen; 2011 Jan; 14(1):9-21. PubMed ID: 20958260
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.
Deutscher SL; Figueroa SD; Kumar SR
Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
8. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
10. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
11. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.
Larimer BM; Thomas WD; Smith GP; Deutscher SL
Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054
[TBL] [Abstract][Full Text] [Related]
12. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
13. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice.
Newton JR; Kelly KA; Mahmood U; Weissleder R; Deutscher SL
Neoplasia; 2006 Sep; 8(9):772-80. PubMed ID: 16984734
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
17. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.
Lütje S; Rijpkema M; Goldenberg DM; van Rij CM; Sharkey RM; McBride WJ; Franssen GM; Frielink C; Helfrich W; Oyen WJ; Boerman OC
Cancer Res; 2014 Nov; 74(21):6216-23. PubMed ID: 25252911
[TBL] [Abstract][Full Text] [Related]
20. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]